VANCOUVER, B.C. — Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced the closing of its previously announced underwritten public offering of 11,035,000 common shares, including the… Read More
VANCOUVER, B.C. — Acuitas Therapeutics is excited to announce that it has entered into a sponsorship agreement with the 2022 Greater Vancouver Regional Science Fair (GVRSF). This is a partner-level… Read More
Recommendation based on pivotal trial that showed Dupixent significantly reduced severe asthma attacks and improved lung function in children aged 6 to 11 Dupixent is the only biologic to show… Read More
Vabysmo (faricimab-svoa) targets and inhibits two disease pathways that drive neovascular or “wet” age-related macular degeneration (nAMD) and diabetic macular edema (DME) Vabysmo is the only injectable eye medicine approved simultaneously in the US for nAMD and DME, with… Read More
Top-tier investor syndicate led by Lux Capital and Leaps by Bayer, with participation from Obvious Ventures, Amgen Ventures, Amplitude Ventures and Air Street Capital. Gandeeva will use the funding to… Read More
